SCAI and HRS have collaborated on new guidelines designed to help clinicians make the safest, smartest treatment decisions possible.

Karen Joynt Maddox, MD, MPH, explained the many ways cardiology's business models are starting to evolve. She also touched on a number of other topics, including AI and the power of prevention.

The interventional device, designed to perform both M-TEER and T-TEER, is at the center of two new studies published in EuroIntervention.

Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker. 

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful. 

John Puskas, MD, chief of cardiothoracic surgery at Emory University Hospital Midtown, noted that both treatment options have their own benefits. It often depends on the patient's age and comorbidities, though there are other factors to consider as well.